Schering/Merck Zetia 6% Market Share Is 1% Ahead Of Goal

Prescription growth for the cholesterol drug Zetia has not come at the expense of the Zetia/Zocor fixed-dose combination Vytorin, Schering says. The penetration rate for Vytorin on managed care formularies is over 75%, the company says.